Second, the present study only assessed the clinical effectiveness of GLP-1RAs in terms of short-term clinical biochemical marker changes (e.g., HbA1c, eGFR), while the hard endpoints of treatments (e.g., cardiovascular disease, death, progression to end-stage renal disease) were not measured
c bit, sn phm khng gy ra vt vng trn p nh nhng sn phm ln nch thng thng khc
Tirzepatide (the active ingredient in Mounjaro) is a dual GIP/GLP-1 agonist that some studies suggest may be even more effective for weight loss
Hyperoxidized PRDX3 as a specific ferroptosis marker
Ordered through our partner lab
But cost should be weighed alongside the other factors below, not treated as the only variable